Compare VEON & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | BLLN |
|---|---|---|
| Founded | 1992 | 2016 |
| Country | United Arab Emirates | United States |
| Employees | N/A | 713 |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2010 | N/A |
| Metric | VEON | BLLN |
|---|---|---|
| Price | $52.29 | $100.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $73.40 | ★ $126.71 |
| AVG Volume (30 Days) | 75.7K | ★ 705.8K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.21 | $46.29 |
| Revenue Next Year | $1.60 | $30.14 |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.00 | $61.96 |
| 52 Week High | $64.00 | $138.70 |
| Indicator | VEON | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 57.19 |
| Support Level | $51.66 | $79.07 |
| Resistance Level | $56.25 | $108.50 |
| Average True Range (ATR) | 2.25 | 7.99 |
| MACD | -0.55 | 0.36 |
| Stochastic Oscillator | 41.69 | 67.12 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.